Aktiia

Aktiia is a company focused on improving the monitoring and management of blood pressure. In 2004, the co-founders started researching non-invasive blood pressure measurement. Between 2005 and 2017, the founders worked at the Swiss Centre for Electronics and Microtechnology (CSEM), where more than 30 techniques were tested and over 10 studies conducted. This research led to one proven approach called Optical Blood Pressure Monitoring, which allows blood pressure to be measured continuously without a cuff. In 2011, Josep Solà completed his PhD, which formed the scientific basis for Aktiia’s technology. The company itself was founded in 2018.

In 2019, clinical trials confirmed that Aktiia’s cuffless method provided accurate readings compared to traditional methods, including arterial line and auscultation measurements. In 2020, the device received a CE Mark as a Class IIa medical device, meeting European medical safety and performance standards. The product was launched in the UK in 2021 and later expanded to six European markets. Over time, Aktiia has collected more than 300 million blood pressure data points from thousands of users across more than 40 countries.

The Aktiia wearable collects an average of 27 automatic blood pressure readings per day, providing continuous data that can be used to understand patterns, track treatment progress, and support medical decision-making. The system includes a bracelet, a mobile app, and a healthcare dashboard. Continuous data enables measurement of Time in Target Range, changes across body positions, and long-term patterns.

Aktiia participates in more than 20 ongoing clinical studies worldwide. Its team includes several PhD-level experts, more than 120 peer-reviewed publications, and over 35 patents. Aktiia supports healthcare providers, digital health services, biopharma companies, and academic research programmes. The aim is to use continuous data and AI-based insights to improve hypertension management and support better health outcomes.

Aktiia’s established in 2004, when its co-founders started exploring new ways to measure blood pressure without using a cuff. At that time, blood pressure monitoring relied mainly on devices that required manual or intermittent measurement, which limited the understanding of how blood pressure changed throughout the day. The founders aimed to find a continuous and non-invasive method that could support long-term observation. 

Between 2005 and 2017, the co-founders joined the Swiss Centre for Electronics and Microtechnology (CSEM). During this period, they tested over 30 scientific techniques and conducted more than 10 clinical and technical studies to find a reliable approach. From this long period of research, one main solution was identified: Optical Blood Pressure Monitoring, which uses light sensors to analyse pulse wave patterns and extract blood pressure values.

In 2011, one of the co-founders, Josep Solà, completed his PhD thesis on continuous non-invasive blood pressure estimation. His research became the basis of the technology that later shaped Aktiia’s medical device and algorithms. After confirming that the method could work in real-world conditions, the founders decided to establish Aktiia as a company in 2018. This allowed them to transfer years of academic and laboratory research into a commercial and medical product.

In 2019, clinical trials took place to verify the accuracy of the cuffless monitoring technology. These studies compared Aktiia’s measurements against arterial line readings and traditional auscultation methods. The results confirmed that the system could produce accurate values in everyday conditions, including when sitting, lying, and standing. In 2020, the device received the CE Mark as a Class IIa medical device, meaning it met European standards for safety and performance. Following this approval, Aktiia launched its product in the UK in early 2021 and soon expanded into Germany, Switzerland, France, Italy, Austria, and Ireland.

As users started wearing the device daily, Aktiia gathered a growing volume of blood pressure data. The company reached milestones of one million, four million, ten million, and eventually more than 200 million blood pressure measurements. These datasets were used in publications in scientific journals, including Nature Scientific Reports and Nature Hypertension, where studies showed that Aktiia’s system provided measurement accuracy comparable to 24-hour ambulatory blood pressure monitors. Further independent studies evaluated the device in different age groups, including elderly populations, and in a variety of physical conditions.

Aktiia also began working with healthcare providers, digital health platforms, and research organisations. The goal was to support hypertension management programmes, remote monitoring services, rehabilitation care, and long-term cardiovascular studies. The device collects an average of 27 blood pressure readings per day automatically, enabling doctors and researchers to study time-based patterns, responses to medication, and daily fluctuations. The company created a healthcare dashboard to allow medical teams to review a patient’s longitudinal data and track outcomes over time.

In addition to healthcare use, the company expanded into research support for biopharma and academic institutions. Aktiia systems have been used in randomised clinical trials, observational studies, real-world evidence projects, and population-level monitoring. The datasets are GDPR and HIPAA compliant, with secure storage and data export options for research analysis. Aktiia has also contributed to standards committees, published academic work, and filed over 35 patents related to its technology.

At present, Aktiia continues to increase its global research footprint, participating in more than 20 clinical studies worldwide.

Aktiia’s mission is to improve the way blood pressure is understood, monitored, and managed in daily life. The organisation aims to provide continuous, accurate, and medical-grade blood pressure data in a simple and non-invasive way, so that both individuals and healthcare professionals can make informed decisions. By collecting regular readings throughout the day and night, Aktiia works to help people understand their own blood pressure patterns and support earlier intervention when needed. The mission also includes enabling health systems, clinics, and researchers to use real-world data to guide treatment, reduce risk, and improve long-term outcomes for people living with hypertension.

Aktiia’s vision is to create a future where blood pressure monitoring is continuous, accessible, and integrated into everyday life. The organisation aims to move away from occasional, manual measurements and towards a model where data is collected automatically, offering a clearer picture of long-term cardiovascular health. Aktiia envisions a world where personalised insights help prevent complications linked to hypertension, and where patients, doctors, and health providers have the information they need to manage blood pressure more effectively. The goal is to support better health outcomes globally by enabling more proactive and informed care, driven by reliable and long-term blood pressure data.

Aktiia has been recognised for its contribution to advancing blood pressure monitoring and cardiovascular health research. The company has received the CE Mark as a Class IIa medical device, confirming compliance with European safety and performance standards. Aktiia’s technology and clinical evidence have been published in respected scientific journals, including Nature Scientific Reports and Nature Hypertension, validating its accuracy and application. 

Its research has been included in over 100 peer-reviewed scientific publications and supported by more than 20 clinical studies worldwide. The organisation’s experts also contribute to ISO and IEEE medical device committees, demonstrating leadership in the development of cuffless blood pressure monitoring standards.

Aktiia provides a continuous, non-invasive blood pressure monitoring system designed for everyday use and for professional healthcare environments. The core of Aktiia’s offering is its medical-grade wearable bracelet, combined with software platforms that organise, analyse, and present blood pressure data in simple and usable formats. The purpose of these products and services is to support long-term blood pressure tracking, allow healthcare providers to monitor patients remotely, and enable researchers to collect reliable real-world cardiovascular data.

The Aktiia Bracelet is the main product. It is a light wearable device that uses optical sensors to measure the changes in blood flow beneath the skin. These signals are processed by Aktiia’s Optical Blood Pressure Monitoring (OBPM) algorithm, which estimates blood pressure automatically, multiple times per day. Unlike traditional cuff devices, the bracelet does not require the user to stop activities or interact with the device to collect readings. It collects an average of 27 measurements per day while being worn normally. This makes it suitable for long-term monitoring, daily use at home, and remote patient management programmes.

The bracelet connects to the Aktiia App, which allows users to view their daily, weekly, and monthly blood pressure patterns. The app records measurements over time, helping individuals understand how their blood pressure changes during different periods of the day, rest, sleep, and activity. The app also displays heart rate information and provides a measure known as Time in Target Range (TTR), which shows how long a person’s blood pressure stays within a clinically recommended range. This helps users and healthcare providers judge whether treatment, lifestyle changes, or medication adjustments are effective.

For healthcare professionals, Aktiia provides the Aktiia Clinical Dashboard. This secure online platform allows doctors, nurses, and care teams to monitor patients’ blood pressure remotely. Each patient’s continuous readings are displayed in clear charts and summaries. The dashboard supports monitoring of treatment progress, medication adherence, and ongoing hypertension management. Healthcare providers can review trends, identify periods of elevated blood pressure, and make data-based decisions without requiring repeated clinic visits. This can help reduce “white coat syndrome”, where patients show artificially high readings in clinical settings.

Aktiia also offers services for research and clinical studies. The system is used in observational studies, remote monitoring trials, cardiovascular rehabilitation programmes, real-world evidence projects, and population health research. The company supplies data in de-identified formats to comply with GDPR, HIPAA, and Good Clinical Practice standards. Researchers can request raw data exports in .CSV format for deeper analysis. Aktiia’s project management team provides training, technical setup, data management support, and guidance throughout the study period to ensure consistent data collection and high participant engagement.

For organisations developing digital healthcare services, telehealth platforms, or cardiovascular management programmes, Aktiia can integrate its system into broader care pathways. The goal is to enable continuous monitoring rather than one-off measurements. This supports earlier intervention, remote patient support, and systematic follow-up without increasing the burden on patients or clinics.